Una propuesta de medicina de precisión en salud mental de Oryzon recibe la distinción de Proyecto de Alta Calidad del programa europeo Eurostars

by Oryzon Genomics

La propuesta ha superado favorablemente todas las fases de la evaluación internacional, incluida la revisión por parte del Independent Evaluation Panel (IEP)

Read more

ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress

by Oryzon Genomics

In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to demo...

Read more

ORYZON initiates patient enrollment in IDEAL Phase II trial of iadademstat in essential thrombocythemia

by Oryzon Genomics

Oryzon Genomics a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that the first patient has been enrolled in IDEAL, its Phase II study evaluating iadadems...

Read more

ORYZON reports financial results and corporate update for quarter ended March 31st, 2026

by Oryzon Genomics

Updated positive data from iadademstat in 1L AML unfit patients to be presented at EHA, with 100% ORR, 93% CRc and 79% strict CR at abstract submission cut-off

Read more

ORYZON to Present Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia at EHA 2026

by Oryzon Genomics

In first line, iadademstat with azacitidine and venetoclax continues to show favorable safety and 100% ORR, with a composite complete remission rate (CRc) of 93% (with 79% CR), and an estimated 12-mon...

Read more

ORYZON to participate in upcoming events in May and June

by Oryzon Genomics

Updated data from iadademstat’s clinical trials in acute myeloid leukemia to be presented at EHA-2026 in June

Read more

ORYZON strengthens vafidemstat patent portfolio with U.S. Notice of Allowance

by Oryzon Genomics

Covers the use of vafidemstat for treating non-aggressive symptoms of Borderline Personality Disorder

Read more

ORYZON announces U.S. patent grant covering iadademstat combinations with venetoclax

by Oryzon Genomics

Oryzon Genomics today announced that the United States Patent and Trademark Office has granted U.S. patent US12,564,559 B2, relating to therapeutic combinations of iadademstat, Oryzon’s potent and s...

Read more

ORYZON expands patent protection for iadademstat with grant decision in Mexico covering combinations with PD-1/PD-L1 inhibitors

by Oryzon Genomics

Oryzon Genomics today announced that the Mexican Patent Office has issued a decision to grant for its patent application MX/a/2021/011610, entitled “Combinations of iadademstat for cancer therapy”...

Read more

ORYZON reports financial results and corporate update for quarter ended December 31st, 2025

by Oryzon Genomics

Investment in R&D reached €12.6 million, representing an increase of 50% (€4.2 million) compared to the €8.4 million invested in the previous financial year.

Read more

ORYZON receives European Medicines Agency approval to initiate a Phase II study of iadademstat in essential thrombocythemia

by Oryzon Genomics

Oryzon Genomics ha anunciado hoy que la Agencia Europea del Medicamento ha aprobado su Solicitud de Autorización de Ensayo Clínico para iniciar un ensayo clínico de Fase II de iadademstat, el inhi...

Read more

ORYZON to participate in upcoming events in February and March

by Oryzon Genomics

Oryzon Genomics, a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Bellvitge identifica una alteración gen...

by Hospital Universitari de Bellvitge

El Hospital Universitario de Bellvitge y el Instituto de Investigació...

Photos Stream